Crinetics Pharmaceuticals, Inc.
CRNX
$46.98
$1.974.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -52.24% | -43.05% | -39.41% | -39.10% | -39.36% |
| Total Depreciation and Amortization | 63.08% | 95.35% | 151.05% | 153.64% | 102.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 33.92% | 36.69% | 44.55% | 48.46% | 67.47% |
| Change in Net Operating Assets | -126.01% | -121.39% | -122.94% | 19.44% | 762.96% |
| Cash from Operations | -73.26% | -67.34% | -47.72% | -37.09% | -23.83% |
| Capital Expenditure | -68.88% | 10.77% | 37.52% | 18.00% | 6.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -260.28% | -72.21% | -170.67% | -191.72% | -61.01% |
| Cash from Investing | -254.30% | -70.54% | -165.65% | -186.82% | -57.42% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 17.05% | -19.32% | -20.43% | 157.62% | 37.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -90.37% | 8.70% | 23.09% | -111.53% | 22.40% |
| Cash from Financing | 14.56% | -19.83% | -20.29% | 160.31% | 41.36% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -218.28% | -194.60% | -184.95% | 843.34% | 55.94% |